Leveraging Homologous Recombination Deficiency via the Repositioned Prodrug CB1954
James L. Elia, Jarvis Hill, Collin D. Heer, Siji Smolev, Abbey M. Sykes, Sofia R. Arbelaez, Karlie N. Lucas, Spenser S. Johnson, Ranjini K. Sundaram, Seth B. Herzon, Ranjit S. Bindra
This paper identifies CB1954 as a selective therapy for BRCA2-deficient cancers by showing its activity in HRD cells and mechanism of action.
bioRxiv · Jul 9, 2026 · PreprintCancer Biology